Entities / Company
Amphastar Pharmaceuticals.
publicly traded American pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 39
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Bank of America reissued an underperform rating for Amphastar Pharmaceuticals on June 29, 2026.Some support4 reports
-
FDA approved Rextovy nasal spray manufactured by Amphastar Pharmaceuticals.Some support1 report
-
Amphastar Pharmaceuticals filed required 13F reports with the SEC on June 6, 2026.Some support1 report
-
Positive inflation data fueled a stock market rally involving Select Medical, Amphastar Pharmaceuticals, and Integra LifeSciences.Some support1 report
-
JPMorgan Chase is facing setbacks regarding its pipeline investments concerning Amphastar Pharmaceuticals.Some support1 report
-
Jack Zhang was appointed President and CEO of Amphastar Pharmaceuticals on July 15, 2025, which is headquartered in Rancho Cucamonga.Some support1 report
-
Amphastar Pharmaceuticals was analyzed using value investing metrics on July 23, 2025.Some support2 reports
-
Silgan Holdings and Amphastar Pharmaceuticals were analyzed as low-volatility stocks and investment opportunities on July 24, 2025.Some support1 report
-
Incepta Pharmaceuticals and Amphastar Pharmaceuticals were ranked in the Generic Drugs industry.Some support1 report2 developments inside
-
Amphastar Pharmaceuticals reported its Q2 financial results on August 6, 2025.Some support4 reports
-
Amphastar Pharmaceuticals appointed Jack Zhang as President and CEO on August 13, 2025, and simultaneously secured an exclusive licensing agreement for peptide development commercialization in Canada.Some support3 reports
-
FDA approved a generic drug, leading to a market rally, involving Amphastar Pharmaceuticals.Some support2 reports1 development inside
-
Amphastar Pharmaceuticals is moving forward with product candidate AMP 002, which is currently under FDA review, alongside plans to expand its domestic manufacturing capacity.Some support1 report
-
Amphastar Pharmaceuticals' outlook was questioned by Wells Fargo, Bank of America, and Needham & Company during an earnings call.Some support2 reports
-
FDA approved generic Iron Sucrose Injection for Amphastar Pharmaceuticals on September 2, 2025.Well supported4 reports
No events began in the chosen period. Widen it, or reset.
Around Amphastar Pharmaceuticals this week
News at the entities that move Amphastar Pharmaceuticals most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Amphastar Pharmaceuticals
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Amphastar Pharmaceuticals
-
Bank of America Mentioned togetherGoldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Moves Amphastar Pharmaceuticals
-
Jefferies Financial Group Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Amphastar Pharmaceuticals
-
Bristol-Myers Squibb OperationalBristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Moves Amphastar Pharmaceuticals
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Amphastar Pharmaceuticals
Connections
The 12 strongest of 39, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Jack Zhang Structural
Jack Zhang holds the formal role of President and CEO of Amphastar Pharmaceuticals.
-
FDA Structural
FDA formally regulates Amphastar Pharmaceuticals by reviewing and approving its drug applications and products.
-
SEC Structural
Amphastar Pharmaceuticals is subject to regulatory oversight and disclosure requirements by the SEC.
-
Bank of America Mentioned together
Bank of America analysts actively track Amphastar Pharmaceuticals, issuing underperform ratings and inquiring about financial performance.
-
Bristol-Myers Squibb Operational
Both companies actively compete within the pharmaceuticals segment.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group issued a rating and price target for Amphastar Pharmaceuticals.
-
Wells Fargo Mentioned together
Wells Fargo analysts are researching and questioning market opportunities within the biosimilar and GLP-1 pharmaceutical sectors.
-
Securities and Exchange Commission Structural
Amphastar Pharmaceuticals is required to file 13F reports with the Securities and Exchange Commission.
Show all 12 connections
-
Incepta Pharmaceuticals Mentioned together
Both companies are identified as operating within the generic drugs sector.
-
Rancho Cucamonga Shared context
Amphastar Pharmaceuticals is located in and operates within Rancho Cucamonga.
-
Rong Zhou Transactional
Rong Zhou, an executive, sold company shares on the market.
-
Nasdaq Shared context
Amphastar Pharmaceuticals' stock is listed and trades on the Nasdaq exchange.
History
Events by the month they beganAugust 2026
1 eventJune 2026
15 events- Bank of America reissued an underperform rating for Amphastar Pharmaceuticals on June 29, 2026.
- FDA approved Rextovy nasal spray manufactured by Amphastar Pharmaceuticals.
- Amphastar Pharmaceuticals filed required 13F reports with the SEC on June 6, 2026.
- Positive inflation data fueled a stock market rally involving Select Medical, Amphastar Pharmaceuticals, and Integra LifeSciences.
- JPMorgan Chase is facing setbacks regarding its pipeline investments concerning Amphastar Pharmaceuticals.
- Jack Zhang was appointed President and CEO of Amphastar Pharmaceuticals on July 15, 2025, which is headquartered in Rancho Cucamonga.
- Amphastar Pharmaceuticals was analyzed using value investing metrics on July 23, 2025.
- Silgan Holdings and Amphastar Pharmaceuticals were analyzed as low-volatility stocks and investment opportunities on July 24, 2025.
- Incepta Pharmaceuticals and Amphastar Pharmaceuticals were ranked in the Generic Drugs industry.
- Amphastar Pharmaceuticals reported its Q2 financial results on August 6, 2025.
- Amphastar Pharmaceuticals appointed Jack Zhang as President and CEO on August 13, 2025, and simultaneously secured an exclusive licensing agreement for peptide development commercialization in Canada.
- FDA approved a generic drug, leading to a market rally, involving Amphastar Pharmaceuticals.
- Amphastar Pharmaceuticals is moving forward with product candidate AMP 002, which is currently under FDA review, alongside plans to expand its domestic manufacturing capacity.
- Amphastar Pharmaceuticals' outlook was questioned by Wells Fargo, Bank of America, and Needham & Company during an earnings call.
- FDA approved generic Iron Sucrose Injection for Amphastar Pharmaceuticals on September 2, 2025.